Clearside Biomedical Inc (CLSD) Return on Investment ROI from the third quarter of 2025 to third quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Clearside Biomedical Inc   (NASDAQ: CLSD)


Clearside Biomedical Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Clearside Biomedical Inc's ROI in the third quarter of 2025?
Clearside Biomedical Inc recorded a cumulative net loss of $-26 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -185.22%.

Within the Healthcare sector 742 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3787 to 4000.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Investment Change TTM -50.33 % -39.99 % -30.09 % -17.97 % -23.49 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 9 12 15 20 24
Return On Investment (TTM) -185.22 % -156.48 % -142.29 % -129.44 % -112.81 %
CLSD's Overall Ranking # 4000 # 3787 # 3615 # 3638 # 3424
Seq. Investment Change TTM -20.75 % -18.21 % -18.4 % -6.08 % -4.25 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -26 -28 -31 -34 -32

CLSD Company Profile >> Back to CLSD Roi Comparisons >> See Annual CLSD Return On Investment



Return On Investment CLSD's Ranking
Within: No.
Industry # 349
Sector # 743
Overall # 4000

Return On Investment Statistics
High Average Low
1.6 %
-120.68 %
-214.49 %
  (Sep 30 2019)



  News about Clearside Biomedical Inc Return on Investment ROI

Clearside Biomedical Appoints Ophthalmology Expert Dr. Glenn Yiu to Scientific Advisory Board Amidst Challenging Financial Results

July 11, 2024


Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS), has announced the appointment of Glenn C. Yiu, M.D., Ph.D., as a new member of its Scientific Advisory Board (SAB). The SAB consists of renowned retinal physicians within the industry, providing valuable medical and scientific expertise for the company s research and development programs.
Dr. Yiu currently holds the position of Professor of Ophthalmology at the University of California, Davis. His extensive knowledge and experience in ophthalmology make him a valuable addition to Clearside Biomedical s SAB. He will bring valuable insights and contribute to the advancement of the company s innovative therapeutic delivery methods.

Exploring the Pioneering Frontier of Suprachoroidal Drug Delivery: Clearside Biomedical's Virtual KOL Event Sheds Light on the Future of Ocular Therapies

June 27, 2024

Clearside Biomedical, a leading biopharmaceutical company specializing in the development of innovative therapies to treat sight-threatening eye diseases, is set to host a virtual Key Opinion Leader (KOL) event on the use and versatility of suprachoroidal drug delivery. The webinar is scheduled to take place on Wednesday, July 24, 2024, at 8:00 am ET.
Suprachoroidal drug delivery is a cutting-edge technique that aims to revolutionize the treatment of ocular diseases by targeting the specific anatomical region behind the eye s retina. Clearside Biomedical has been at the forefront of harnessing this advanced drug delivery method to improve the lives of patients suffering from various eye conditions.

Clearside Biomedical Appoints Chief Medical Officer with Extensive Retinal Disease Research Background Amidst Financial Struggles

March 18, 2024



Clearside Biomedical Inc, a biopharmaceutical company specializing in retinal disease research and clinical development, recently announced the appointment of Victor Chong, M.D., MBA as their Chief Medical Officer. Dr. Chong brings with him a wealth of experience and a proven track record in advancing programs through clinical development, making him a valuable addition to the company s leadership team. However, this news comes in the backdrop of Clearside Biomedical recording a significant net loss and negative return on investment in the last year.
According to the financial reports, Clearside Biomedical Inc reported a cumulative net loss of -$37 million during the 12 months ending in the third quarter of 2023. This has resulted in a negative return on investment (ROI) of -101.04% for the company. These figures indicate that the company has been facing challenging financial circumstances, which naturally raises concerns about its future stability and viability.





Financial Statements
Clearside Biomedical Inc's III. Quarter Investments $ 9 Millions CLSD's Balance sheet
Clearside Biomedical Inc's III. Quarter Income $ -6 Millions Quarterly CLSD's Income Statement
CLSD's Income by Division See CLSD's Income by Division


CLSD Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 20 27 46 38 9
Y / Y Investment Growth -25.26 % -40.24 % 19.87 % 333.36 % -41.49 %
Net Income in Millions -34 -32 -33 0 -18
Y / Y Net Income Growth - - - - -
Annual Return On Investment -168.96 % -119.41 % -72.38 % 0.99 % -207.81 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CLSD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CLSD's Competitors
Subscribers only: Roi for Clearside Biomedical Inc's Suppliers
Subscribers only: Return On Investment for CLSD's Customers

Other Ratios
CLSD's Roa CLSD's Inventory Turnover Ratio CLSD's Growth Rates CLSD's Dividend Statistics
CLSD's Profitability Ratios CLSD's Asset Turnover Ratio CLSD's Dividend Growth
CLSD's Roe CLSD's Valuation Ratios CLSD's Financial Strength Ratios CLSD's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-26T07:29:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.